Phase II clinical study of TY-0201 in patients with chronic heart failure

TOA EIYO LTD.0 个研究点目标入组 40 人开始时间: 2014年8月29日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with chronic heart failure due to ischemic heart disease, dilated cardiomyopathy or dilated phase of hypertrophic cardiomyopathy.
•2) New York Heart Association (NYHA) class I, II or III.
•3) Patients diagnosed with chronic heart failure and confirmed =< 40 % of left ventricular ejection fraction (LVEF) before the day of informed consent.
•4) Patients whose medication for chronic heart failure has been optimized without any change of the dosage and administration.
•5) Outpatients

•1) Patients without the implantation of pacemaker and whose pulse rate are < 50 beats/min.
•2) Systolic blood pressure < 90 mmHg.
•3) Patients with complication of hypertrophic obstructive cardiomyopathy, cardiogenic shock, severe valve stenosis or valve regurgitation, severe or multiple arrhythmia, or secondary cardiomyopathy with rapid deterioration.
•4) Patients with poor skin condition at the patch application site or history of dermatitis due to a topical agent, etc.

发起方